
July 2 (Reuters) - Organon & Co OGN.N:
ORGANON PROVIDES UPDATE ON PHASE 2 ELENA PROOF-OF-CONCEPT STUDY EVALUATING OG-6219 IN PATIENTS WITH ENDOMETRIOSIS-RELATED PAIN
ORGANON & CO - PHASE 2 STUDY ON OG-6219 DID NOT MEET PRIMARY ENDPOINT
ORGANON & CO - TO DISCONTINUE OG-6219 CLINICAL DEVELOPMENT PROGRAM
ORGANON & CO - OG-6219 DID NOT IMPROVE ENDOMETRIOSIS-RELATED PAIN COMPARED TO PLACEBO